Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)-Reference-Cited by-同舟云学术

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

Published:2014-11-14 Issue:6 Volume:171 Page:1318-1325
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Chalmers J.R.¹,Schmitt J.²,Apfelbacher C.³,Dohil M.⁴,Eichenfield L.F.⁴,Simpson E.L.⁵,Singh J.⁶,Spuls P.⁷,Thomas K.S.¹,Admani S.⁴,Aoki V.⁸,Ardeleanu M.⁹,Barbarot S.¹⁰,Berger T.¹¹,Bergman J.N.¹²,Block J.¹³,Borok N.⁴,Burton T.¹⁴,Chamlin S.L.¹⁵,Deckert S.²,DeKlotz C.C.⁴,Graff L.B.¹⁶,Hanifin J.M.⁵,Hebert A.A.¹⁷,Humphreys R.¹⁸,Katoh N.¹⁹,Kisa R.M.²⁰,Margolis D.J.²¹,Merhand S.²²,Minnillo R.²³,Mizutani H.²⁴,Nankervis H.¹,Ohya Y.²⁵,Rodgers P.²⁶,Schram M.E.⁷,Stalder J.F.²⁷,Svensson A.²⁸,Takaoka R.⁸,Teper A.²⁹,Tom W.L.⁴,von Kobyletzki L.³⁰,Weisshaar E.³¹,Zelt S.³²,Williams H.C.¹

Affiliation:

1. Centre of Evidence-Based Dermatology; University of Nottingham; Nottingham U.K

2. Centre for Evidence-Based Healthcare; University of Dresden; Dresden Germany

3. Department of Epidemiology and Preventive Medicine; University of Regensburg; Regensburg Germany

4. Rady Children's Hospital; University of California; San Diego CA U.S.A

5. Department of Dermatology; Oregon Health and Science University; Portland OR U.S.A

6. Medicine Service; Birmingham VA Medical Center and Department of Medicine; University of Alabama; Birmingham AL U.S.A

7. Department of Dermatology; Academic Medical Center; University of Amsterdam; Amsterdam the Netherlands

8. Department of Dermatology; University of Sao Paulo; Sao Paulo Brazil

9. Clinical Sciences; Immunology and Inflammation; Regeneron Pharmaceuticals; Tarrytown NY U.S.A

10. Department of Dermatology CHU Nantes; Nantes France

11. Department of Dermatology; University of California; San Francisco CA U.S.A

12. Pediatric Allergy and Dermatology Centre; University of British Columbia; Vancouver BC Canada

13. National Eczema Association; San Rafael CA U.S.A

14. Patient Representative; Centre of Evidence-Based Dermatology; University of Nottingham; Nottingham U.K

15. Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago IL U.S.A

16. LEO Pharma A/S; Ballerup Denmark

17. Department of Dermatology; University of Texas Medical School; Houston TX U.S.A

18. National Eczema Society; London U.K

19. Department of Dermatology; Kyoto Prefectural University of Medicine; Kyoto Japan

20. Pierre Fabre Pharmaceuticals; New York NY U.S.A

21. Department of Dermatology; University of Pennsylvania; Philadelphia PA U.S.A

22. French Association of Eczema; Redon France

23. Society for Investigative Dermatology; Cleveland OH U.S.A

24. Department of Dermatology; Mie University; Tsu Japan

25. Division of Allergy; National Centre for Child Health and Development; Tokyo Japan

26. LEO Pharma; Parsippany NJ U.S.A

27. Department of Dermatology; Nantes University Hospital; Nantes France

28. Department of Dermatology; University Hospital Malmo; Malmo Sweden

29. Sanofi Aventis; Hastings-on-Hudson NY U.S.A

30. Department of Dermatology and Venerology; Lund University; Lund Sweden

31. Department of Clinical Social Medicine; University Hospital Heidelberg; Heidelberg Germany

32. Stiefel Laboratories; Research Triangle Park NC U.S.A

Funder

National Institute for Health Research

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.13237/fullpdf

Reference15 articles.

1. Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany;Schmitt;Br J Dermatol,2010

2. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting;Schmitt;Allergy,2012

3. Scoring the severity of atopic dermatitis: three Item Severity score as a rough system for daily practice and as a pre-screening tool for studies;Wolkerstorfer;Acta Derm Venereol,1999

4. Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation;Schmitt;J Allergy Clin Immunol,2013

5. The OMERACT filter for outcome measures in rheumatology;Boers;J Rheumatol,1998

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use;Journal of the European Academy of Dermatology and Venereology;2024-08-19

2. Measuring Signs of Atopic Dermatitis in Clinical Practice;JAMA Dermatology;2024-08-01

3. Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial;Acta Dermato-Venereologica;2024-02-12

4. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum (PG) in Clinical Trials: A Delphi Consensus on Behalf of the Understanding PG: Review and Assessment of Disease Effects (UPGRADE) Group;Journal of Investigative Dermatology;2023-12

5. A core domain set for pyoderma gangrenosum trial outcomes - an international e-Delphi and consensus study from the UPGRADE initiative;British Journal of Dermatology;2023-11-11